Another ‘Fallen Angel’ from Cramer on CNBC’s MAD MONEY is Amgen (AMGN-NASDAQ) after it got crushed last week. He said this is much to do about nothing. The headline risk was that Aranesp was causing deaths and while it was scary it wasn’t the blow-up because the patients all were active cancer patients that were no longer taking chemo or undergoing treatment. The $4.30 to $4.50 per share guidance is very acceptable considering they are conservative. The earnings growth is more than the negatives. Amgen is also on the offensive against Roche on a patent case. The pipeline has an Imclone competitor and the Phase III bone drug could be a big blockbuster. He thinks this is the second best drug play in the world behind Genentech and all the bad news is behind it.
This one is the one we noted last week that is no longer comparable to biotechs and it is trading like a plain jane drug stock. AMGN traded up 1.25% to $70.85 in after-hours trading.
Jon C. Ogg
January 29, 2007
Sponsored: Want to Retire Early? Here’s a Great First Step
Want retirement to come a few years earlier than you’d planned? Orare you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
